Testicular Cancer
Testicular Germ Cell Tumors - Seminoma and Non-Seminoma
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not applicable (managed per AUA/EAU oncology guidelines)
Reference only. Not medical advice.
What can go wrong
Beyond the cancer itself: infertility, hypogonadism (fatigue, low libido, ED), anejaculation after RPLND, cardiovascular and metabolic sequelae, and a lifelong elevated risk of a second primary cancer (higher after seminoma). Trans-scrotal biopsy is contraindicated because it can seed tumor. Long-term platinum exposure and its systemic effects make structured survivorship care essential.
This is something to take to a clinician. The Atlas can tell you what is known about testicular cancer in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Testicular germ cell tumor is the most common solid malignancy in men aged roughly 15-40, split into seminoma and non-seminoma. Incidence has risen for decades (Dutch data show seminoma rising to ~11.4 and non-seminoma to ~11.1 per 100,000 person-years by 2019). It is one of oncology's great success stories: overall 5-year survival is about 95% (near 99% for seminoma, ~88% for non-seminoma), and cure is achievable in ~95% overall and ~80% even with metastatic disease. Radical inguinal orchiectomy is both diagnostic and therapeutic. The catch is the survivorship burden: impaired fertility and hypogonadism.
The young man's cancer with a remarkable cure rate - and a fertility aftermath.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Most germ cell tumors arise from germ cell neoplasia in situ (GCNIS), a precursor lesion linked to the testicular dysgenesis syndrome hypothesis (undescended testis, poor semen quality, and cancer sharing developmental roots). Seminomas resemble undifferentiated germ cells and are exquisitely radio- and chemosensitive; non-seminomas (embryonal carcinoma, yolk sac, choriocarcinoma, teratoma) are more heterogeneous. Serum tumor markers AFP, beta-hCG, and LDH aid diagnosis, staging, and monitoring.
The catch: cured of cancer, left with a fertility and hormone deficit
The fertility and hormone fallout is multifactorial and often predates treatment: many men already have impaired semen quality at diagnosis because the same dysgenic process that seeded the tumor also impaired the contralateral testis. Then cisplatin-based chemotherapy is among the most spermatotoxic regimens, radiotherapy scatters dose to the remaining testis, and RPLND can cause anejaculation via sympathetic nerve injury. Hypogonadism follows in 15% to over 40% of survivors, worsening with treatment intensity (odds rising from surgery alone through radiotherapy to high-dose chemotherapy) - partly from residual circulating platinum chronically exposing the remaining testis. Leydig cells are relatively radioresistant (needing >20-30 Gy), which is why testosterone often survives radiation better than sperm production.
When this is an emergency
Usually a painless testicular lump or swelling found by the patient or a partner; scrotal ultrasound characterizes the mass and serum AFP/beta-hCG/LDH support diagnosis and staging. Definitive diagnosis is by radical inguinal orchiectomy with histology. Staging CT and marker trends guide subsequent therapy.
Safety in detail
This is a malignancy requiring urgent evaluation and multidisciplinary oncologic care. A painless testicular mass in a young man must be assessed by a physician promptly; self-diagnosis or delay costs lives and options.
What it does to fertility
Central to this entry. Baseline semen impairment is common at diagnosis; orchiectomy halves testicular mass; chemotherapy (cisplatin) is highly spermatotoxic; radiotherapy scatters to the remaining testis; and RPLND can abolish antegrade ejaculation. Pre-treatment sperm banking is strongly recommended. Some men recover spermatogenesis over 1-2+ years; azoospermic survivors may still yield sperm on surgical retrieval. Hypogonadism (15% to >40%) may need testosterone therapy - which itself suppresses any residual fertility, creating a management tension.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Serum tumor markers (AFP, beta-hCG, LDH)
- Staging and surveillance imaging
- Post-treatment testosterone/LH/FSH for hypogonadism
- Semen analysis for fertility counseling
- Long-term surveillance for second primary cancers and cardiovascular/metabolic effects
What people get wrong
Often saidLosing a testicle to cancer means infertility
ActuallyMany men retain fertility with one healthy testis, but semen quality is often already impaired at diagnosis and treatment can worsen it - which is exactly why sperm banking before treatment is recommended.
Often saidTesticular cancer is usually fatal
ActuallyThe opposite - it is among the most curable solid cancers, with ~95% overall 5-year survival and cure even in most metastatic cases.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
How we got here
The transformation of testicular cancer from lethal to curable followed the introduction of cisplatin-based chemotherapy in the 1970s (Einhorn's regimens), one of the landmark achievements of medical oncology. Rising incidence over decades has focused attention on testicular dysgenesis syndrome and environmental/developmental risk factors.
- 1970sCisplatin-based chemotherapy transforms cure rates (Einhorn)
- 1990s-2000sSurvival exceeds 95%; survivorship issues gain attention
- 2019/2023AUA early-stage guideline formalizes fertility counseling and survivorship
- ongoingIncidence continues to rise across high-income countries
The people taking it
Young men 15-40, with higher rates in white men and in those with cryptorchidism, prior contralateral tumor, family history, or infertility.
What we do not know
- What drives the secular rise in incidence?
- Can less-toxic regimens preserve cure rates while sparing fertility and endocrine function?
- How should testosterone replacement be timed against fertility goals in survivors?
At a glance
- Peak age
- ~15-40 years (most common solid tumor in this group)
- 5-year survival
- ~95% overall (seminoma ~99%, non-seminoma ~88%)
- Cure rate
- ~95% overall; ~80% with metastatic disease
- Hypogonadism after treatment
- ~15% to >40% of survivors
- Primary treatment
- Radical inguinal orchiectomy (never trans-scrotal biopsy)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Testicular Cancer. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Dutch AYA incidence study (1989-2019)2024
Documents the sustained rise in both seminoma and non-seminoma incidence
AUA Guideline: Diagnosis and Treatment of Early-Stage Testicular Cancer2019, amended 2023
Standardizes orchiectomy, staging, surveillance, and survivorship, including fertility counseling
Systematic review of hypogonadism and sexual dysfunction in survivors2019
Prevalence 15% to >40%; risk rises with treatment intensity and residual platinum